German biopharma company InflaRx goes public
Germany-based InflaRx, a developer of new therapeutics in the "terminal complement space," has raised about $100 million for its IPO after pricing its over 6.6 million shares at $15 per share. The stock began trading November 8, 2017 on the NASDAQ under the ticker symbol "IFRX." J.P. Morgan, Leerink Partners and BMO Capital Markets are the lead underwriters. InflaRx's backers include Bain Capital Life Sciences LP, Cormorant Asset Management LLC and RA Capital Management LLC.
8 November 2017•2 mins read
